PacBio will discuss Q4 2025 financial results on February 12, 2026, at 5 PM ET via webcast.
Quiver AI Summary
PacBio announced that it will hold a quarterly conference call on February 12, 2026, at 5:00 pm Eastern Time to discuss its financial results for the fourth quarter and full year of 2025. The call will be available via webcast on PacBio's website, and participants can also listen live or access a replay using a provided toll-free number. PacBio, a leading life science technology company, specializes in advanced sequencing solutions for a variety of research applications. For further details, interested parties are encouraged to visit the company's website or contact the investor relations and media teams directly.
Potential Positives
- PacBio is proactively engaging with investors by scheduling a quarterly conference call to discuss its financial results, which demonstrates transparency and commitment to shareholder communication.
- The announcement includes specific details for accessing the conference call, improving accessibility for investors and analysts to stay informed about the company's performance.
- PacBio's products and technologies continue to address a broad range of critical research applications, showcasing the company's relevance and innovation in the life sciences sector.
Potential Negatives
- None
FAQ
When is PacBio's quarterly conference call for Q4 2025 results?
PacBio's quarterly conference call is scheduled for February 12, 2026, at 5:00 pm Eastern Time.
How can I listen to the PacBio conference call?
You can listen to the conference call live or access the replay on PacBio's investor website at https://investor.pacificbiosciences.com/.
What is PacBio's stock symbol?
PacBio is traded on the NASDAQ under the stock symbol PACB.
What technologies does PacBio develop?
PacBio develops advanced sequencing solutions, including HiFi long-read sequencing for various research applications.
Are PacBio products for diagnostic use?
No, PacBio products are provided for Research Use Only and are not for diagnostic procedures.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PACB Insider Trading Activity
$PACB insiders have traded $PACB stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $PACB stock by insiders over the last 6 months:
- OENE MARK VAN (See Remarks) sold 26,836 shares for an estimated $35,181
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PACB Revenue
$PACB had revenues of $2.8M in Q4 2024. This is a decrease of -6.97% from the same period in the prior year.
You can track PACB financials on Quiver Quantitative's PACB stock page.
$PACB Hedge Fund Activity
We have seen 89 institutional investors add shares of $PACB stock to their portfolio, and 86 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MADRONE ADVISORS, LLC removed 11,786,127 shares (-70.3%) from their portfolio in Q3 2025, for an estimated $15,086,242
- ARK INVESTMENT MANAGEMENT LLC removed 5,374,060 shares (-14.8%) from their portfolio in Q3 2025, for an estimated $6,878,796
- MILLENNIUM MANAGEMENT LLC added 4,048,555 shares (+466.3%) to their portfolio in Q3 2025, for an estimated $5,182,150
- EDMOND DE ROTHSCHILD HOLDING S.A. removed 2,691,000 shares (-20.1%) from their portfolio in Q3 2025, for an estimated $3,444,480
- CITADEL ADVISORS LLC added 2,498,354 shares (+inf%) to their portfolio in Q3 2025, for an estimated $3,197,893
- POINT72 (DIFC) LTD added 1,811,137 shares (+73.7%) to their portfolio in Q3 2025, for an estimated $2,318,255
- NATIONAL BANK OF CANADA /FI/ removed 1,084,578 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,388,259
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PACB Analyst Ratings
Wall Street analysts have issued reports on $PACB in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stephens & Co. issued a "Overweight" rating on 11/10/2025
To track analyst ratings and price targets for $PACB, check out Quiver Quantitative's $PACB forecast page.
$PACB Price Targets
Multiple analysts have issued price targets for $PACB recently. We have seen 3 analysts offer price targets for $PACB in the last 6 months, with a median target of $2.0.
Here are some recent targets:
- Luke Sergott from Barclays set a target price of $2.0 on 12/15/2025
- David Westenberg from Piper Sandler set a target price of $2.0 on 11/11/2025
- Mason Carrico from Stephens & Co. set a target price of $2.0 on 11/10/2025
Full Release
MENLO PARK, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, at 5:00 pm Eastern Time.
The call will be webcast and may be accessed at PacBio’s website at https://investor.pacificbiosciences.com/ .
Date: Thursday, February 12, 2026, at 5:00 pm ET (2:00 pm PT)
Listen live via internet or replay:
https://investor.pacificbiosciences.com/
Toll-free: 1-888-349-0136
International: 1-412-317-0459
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Contacts
Investors:
Jim Gibson
[email protected]
Media:
[email protected]
